We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Pooling Strategy Increases Efficiency and Reduces Cost of COVID-19 PCR Tests

By LabMedica International staff writers
Posted on 31 Aug 2020
A new way of manipulating samples for COVID-19 testing of asymptomatic and symptomatic individuals provides both an eight-fold increase in testing efficiency, as well as an eight-fold reduction in test costs.

Recent reports have suggested that10-30% of SARS-CoV-2 (COVID-19) infected patients are asymptomatic and that significant viral shedding may occur prior to symptom onset. More...
Therefore, there is an urgent need to increase diagnostic testing capabilities to prevent disease spread. A major bottleneck of managing the COVID-19 pandemic in many countries is diagnostic testing, which is primarily performed on symptomatic patients, due to limited laboratory capabilities as well as limited access to genome-extraction and PCR (Polymerase Chain Reaction) reagents.

To break this bottleneck, investigators at Ben-Gurion University of the Negev (Beer Sheva, Israel) developed P-BEST, a method for Pooling-Based Efficient SARS-CoV-2 Testing, which identifies all positive subjects within a large set of samples using a single round of testing.

In the P-BEST approach, each individual’s sample is assigned into multiple pools using a combinatorial pooling strategy based on compressed sensing designed for maximizing carrier detection. In the pilot study, the investigators pooled sets of 384 samples into 48 pools, which provided both an eight-fold increase in testing efficiency, as well as an eight-fold reduction in test costs.

Results revealed that the P-BEST method successfully identified up to five positive carriers within sets of 384 samples. P-BEST could be configured based on the carrier rate of a given population. Thus, if the carrier rate was below 1.3%, the method provided both an eight-fold improvement in testing efficiency as well as an eight-fold reduction in test costs.

"Approximately 10-30% of COVID-19 infected patients are asymptomatic and significant viral spread can occur days before symptom onset," said contributing author Dr. Angel Porgador, deputy vice-president of research and development at Ben Gurion University of the Negev. "Until there is a vaccine, there will be an urgent need to increase diagnostic testing capabilities to allow for screening of asymptomatic and pre-symptomatic populations. This new single stage diagnostic test will help prevent the spread of the disease by identifying these patients sooner and at a lower cost using significantly fewer tests."

The P-BEST method was described in the August 21, 2020, online edition of the journal Science Advances.

Related Links:
Ben-Gurion University of the Negev


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: Sophie Paczesny, M.D., Ph.D and her team have made BIOPREVENT freely available for researchers and clinician to test and learn from (Photo courtesy of Cliff Rhodes)

AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear

Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.